CME/CE - PACE-CME

49-64 of 160

Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
MinuteCE®
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Potassium Binders: Safety Comes First!
Potassium Binders: Safety Comes First!
MinuteCE®
Potassium Binders: Safety Comes First!
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
MinuteCE®
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
James Burton, DM, FRCP; Javed Butler, MD, MPH, MBA
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD, MPH, MBA
1.00 program credit
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
MinuteCE®
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
James Burton, DM, FRCP; Patrick Rossignol, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Patrick Rossignol, MD, PhD
1.00 program credit
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
MinuteCE®
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
MinuteCE®
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
James Burton, DM, FRCP; Javed Butler, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 credit 9 episodes
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
CME/CE
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
CME/CE
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Javed Butler, MD
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
CME/CE
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU; Amy Mottl, MD, MPH
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CE
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH; Prof. Christoph Wanner
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CE
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Muthiah Vaduganathan, MD, MPH; Anu Lala, MD
1.00 credit
- Muthiah Vaduganathan, MD, MPH
- Anu Lala, MD
- Brendon Neuen, MBBS, PhD
1.00 credit
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Albuminuria Change and Finerenone's Effect on CV Outcomes
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Key Clinical Trial Insights on Nonsteroidal MRAs in CKM Syndrome Management
Albuminuria Change and Finerenone's Effect on CV Outcomes
Finnian R. McCausland, MD
- Finnian R. McCausland, MD
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CE
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink; Jennifer B. Green, MD
0.25 credits
- prof. Hiddo Heerspink
- Jennifer B. Green, MD
0.25 credits

4/9